REG-Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Globe Newswire•21/08/2026•09:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.